Homozygous Familial Hypercholesterolemia (HoFH) Pipeline Analysis report covers 7 drugs currently in different phases of development. HoFH is an inherited rare disorder characterised by difficult lipoprotein metabolism and extremely high level of circulating low density lipoprotein cholesterol (ranging between 500 and 1200 mg/dl.). These high level of cholesterol accumulates in the arteries leading to cardiovascular disease much faster than in the normal population. The disease is caused due to the mutation of both alleles of the LDL-receptor (LDLR) gene. Clinical manifestations of the HoFH incliclude elevated levels of LDLC, xanthomata and premature cardiovascular disease.
The report provides Homozygous Familial Hypercholesterolemia (HoFH) treatment drugs by company, phases of development including products in early discovery stage and NDA filing, molecule type, route of administration and region. The report will help to evaluate the collaboration, in-licensing and out-licensing opportunities, formulating business development strategies and tracking the activities of the key market players. Epidemiology, major drivers, restraints, and opportunities have been covered to provide an exhaustive picture of the market. The analysis presents in-depth information regarding the development, trends, and industry policies and regulations implemented to offer stakeholders a better understanding of the key factors affecting the overall market environment.
Various databases (for patents and Clinical Trials), studies and data published by industry associations, analyst reports, investor presentations, press releases and journals among others have been taken into consideration while conducting the secondary research.
Market intelligence is presented in the form of analysis, charts, and graphics to help the clients in gaining faster and efficient understanding of the market.
Major industry players profiled as part of the report are Akcea Therapeutics, Regeneron Pharmaceuticals Inc. and The Medicines Company among others.
Scope:
By Company
By Phase
By Molecule Type
By Region
By Route of Administration